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Introduction 
The number of patients with end-stage heart failure (HF) benefiting from 
mechanical circulatory support based therapy is rapidly growing. Over the last 2 
decades the therapy has been rapidly evolving particularly since the introduction 
of continuous flow ventricular assist devices (CF-LVAD) which addressed several 
limitations of the first generation pulsatile devices.  According to the sixth 
INTERMACS registry annual report, the 12 and 24 months overall actuarial 
survival of CF-LVAD was 80% and 70% respectively.1 Survival rates remained 
unchanged over the past 6 years. The adverse events associated with CF-LVAD 
have been dramatically reduced when compared to rates associated with the 
previous generation pulsatile flow devices. The burden of adverse events 
associated with CF-LVAD decreased over the last 6 years and quality of life 
improvement at 12 and 24 months remained consistent. According to the report, 
while the proportion of patients implanted while stable on inotropic support has 
significantly increased in the last era (2011-2013), the expansion into 
INTERMACS levels 4 and higher remains limited to 20%. 
In order to further reduce the adverse events associated with LVAD and expand 
the access to the therapy, Thoratec Corporation sponsored and conducted 
several post-marketing studies. These studies are focused on improving clinical 
outcomes, expanding mechanical circulatory support patient population and 
advancing clinical science. These studies are either Thoratec or single and/or 
multi-center investigator sponsored studies. A summary of the Thoratec 
sponsored studies and the multi-center investigator sponsored studies and their 
anticipated impact is described. 
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Studies Focused on Expanding LVAD Patient Population  
ROADMAP (Risk Assessment and Comparative Effectiveness Of Left Ventricular 
Assist Device and Medical Management in Ambulatory Heart Failure Patients)  
While LVAD therapy is well established for the treatment of advanced HF 
patients requiring intravenous inotropic support, its role in ambulatory non-
inotrope dependent HF patients is still unknown. To help characterize and define 
the patients who benefit from LVAD therapy instead of remaining on optimal 
medical management, the ROADMAP study was designed and conducted.  
ROADMAP is a prospective, multi-center, non-randomized, controlled 
observational study of 200 patients with advanced Class III or ambulatory Class 
IV symptoms who meet the current FDA indications for LVAD and who are either 
maintained on optimal medical management or receive a HeartMate II. The 
primary endpoint of ROADMAP is a composite of survival on original therapy and 
improvement in 6 minute walk distance of ≥ 75 meters at 12 months. In addition 
several secondary endpoints will be assessed and these include a risk stratified 
subgroup analysis of the primary endpoint and temporal analysis of primary 
endpoint at 6, 12, 18, and 24 months, accuracy of prognostic survival risk models 
including Seattle Heart Failure Model and HeartMate II Risk Score, quality of Life 
using the EQ-5D-5L Health Utility Index, depression using Patient Health 
Questionnaire-9, questionnaire on patient decisions related to LVAD therapy 
versus optimal medical therapy. Additional information on ROADMAP can be 
found on ClinicalTrials.gov (identifier: NCT01452802). As of July 2013, the study 
was fully enrolled with 97 patients received a HMII and 103 patients were on 
optimal medical management. Study results will be presented at major 
conferences in the near future.   
SEE-HF (Screening for Advanced Heart Failure Treatment)  
The objective of SEE-HF, a Thoratec sponsored study, is to determine the 
proportion of HF patients followed in outpatient CRT/ICD clinics who are NYHA 
Class III-IV with LVEF < 40% and who have an indication without contraindication 
for heart transplantation and/or DT LVAD.  It is hypothesized that among all CRT 
and/or ICD patients with NYHA III-IV HF, with LVEF <40%, the number of 
patients who have an indication without contraindication for heart transplant or 
LVAD is between 7 and 13% (10±3%). The data from this study will help 
identifying patients in CRT/ICD clinics who may benefit from early consultation 
with an advanced HF cardiologist.  Additional information on SEE-HF can be 
found on ClinicalTrials.gov (identifier: NCT01626404). The study is currently 
enrolling at 8 European sites.  
Studies Focused on Improving Clinical Outcomes 
TRACE (STudy of Reduced Anti-Coagulation/Anti-platelEt Therapy in Patients 
with the HeartMate II LVAS)  
Despite current recommendations to treat LVAD patients with both warfarin and 
aspirin, those who bleed often require a reduction in their antithrombotic 
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therapies. To document and characterize patients who can be safely managed 
with a reduced anti-thrombotic (RT) therapy, TRACE was initiated in the US and 
Europe.  An RT is defined as aspirin only; warfarin or vitamin K antagonist only, 
or no anti-platelet and anti-coagulation. The primary study endpoint is the rate of 
thromboembolic (i.e. ischemic stroke, transient ischemic attack, or pump 
thrombosis) and hemorrhagic events (i.e. bleeding and hemorrhagic stroke). The 
secondary endpoint is to characterize the patient population who can be safely 
maintained on RT. Additional information on TRACE can be found on 
ClinicalTrials.gov (identifier: NCT01477528). Enrollment in the study was 
completed as of July 2013 and enrolled 203 patients from 9 US sites (100 
patients) and 9 European sites (103 patients).  While in the US the reason for RT 
initiation was in response to bleeding events, in Europe all HeartMate II patients 
are managed without anti-platelet agents. Because of the resulting inherent 
difference in the patient populations, the results from both cohorts are being 
analyzed and reported separately.  Initial results from the study were presented 
at the 2014 ISHLT conference.  
As reported by Katz et al., in the first year of RT, among the US cohort there 
were 29 bleeding events, 6 ischemic and 0 hemorrhagic strokes and 4 pump 
thrombosis events.2 The freedom from bleeding, ischemic stroke, hemorrhagic 
stroke, and pump thrombosis were 66%, 94%, 100%, and 95%, respectively. 
These initial results suggest that reducing anti-thrombotic therapies on a chronic 
basis in response to persistent non-surgical bleeding events may be safe in 
selected patients. 
As reported by Netuka et al., in the first year post-RT (vitamin K antagonist  
only),in the European cohort freedom from ischemic stroke, hemorrhagic stroke, 
and device thrombosis post initiation of RT therapy were 95%, 98%, and 96% 
respectively.3 Nine patients (12%) experienced a bleeding event while on RT 
therapy.  It is important to note that while no anti-platelet therapy was used, the 
median INR was 2.3. The preliminary results from the European TRACE cohort 
suggest that in selected patients, single therapy with relatively high INR target is 
associated with a low risk of bleeding and thromboembolic events.  
SSI (Driveline Silicone Skin Interface Registry) 
Single center experience has suggested reduction in driveline infection rates 
after changing the surgical tunneling technique to keep the entire driveline velour 
portion in the subcutaneous tunnel. This results in a Silicone-to-Skin Interface 
(SSI) at the exit site. To assess the long term freedom from driveline infection 
associated with this technique, a multi-center SSI registry was initiated and 
conducted. It is hypothesized that the modified tunneling technique is associated 
with at least 50% reduction in driveline infection at one year post implant when 
compared to the velour-to-skin method used in the HMII Destination Therapy 
(DT) trial. The study includes a retrospective and a prospective cohort which are 
independently powered to achieve the study primary endpoint. Additional 
information on TRACE can be found on ClinicalTrials.gov (identifier: 
NCT01577433). As of July 2013, enrollment of 400 patients from 15 US sites 
was completed.  
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Dean et al. reported on results from the retrospective cohort at the 2014 ISHLT 
conference.4 The actuarial freedom from driveline infection was 93% and 84% at 
12 and 24 months respectively. These rates are significantly lower when 
compared to the corresponding rates in the HMII DT trial of 77% and 65% at 12 
and 24 months post implant. These results suggest that leaving the entire 
driveline velour portion below the skin is associated with a significant reduction in 
driveline infection when compared to results from the HMII DT trial.  
RESIST (REduce Driveline Trauma Through StabIlization and Exit Site 
ManagemenT) 
Driveline infections in patients with LVADs are usually secondary to trauma to the 
exit site. The percutaneous lead management kit (PLMK) was developed for the 
HeartMateII LVAD using commercially available components for driveline 
stabilization and management. The purpose of the RESIST study was to 
evaluate the wearability and usability of the PLMK for a minimum of 30 days. 
Additional information on RESIST can be found on ClinicalTrials.gov (identifier: 
NCT01485666). The study completed enrollment of 50 patients from 5 US sites. 
Stahovich et al. presented results from the study at the 2014 ISHLT conference.5 
At 30days, significantly more patients found the PLMK to be extremely 
comfortable (80% vs. 37%, p<0.001) and extremely effective at stabilizing the 
driveline (82% vs. 40%, p<0.001) compared to before the PLMK. Ease of use 
was similar for PLMK compared to before (72% vs. 57%, p= 0.19). Dressing 
change frequency was a minimum of 6-7 days or more for 85% of the patients, 
which was less frequent than their standard of care. There were 4 patients (8%) 
who stopped using the kit within the first 30 days due to skin irritation (n= 3) and 
driveline infection (n= 1). The PLMK is easy to use, increases patient comfort, 
and increases driveline stability with a dressing change frequency of 6-7 days. 
This kit may therefore help reduce the risk of trauma to the exit site, increase 
patient compliance, and reduce the risk of driveline infections.  
PREVENT (PREVENtion of HeartMate II Pump Thrombosis Through Clinical 
Management)  
Pump thrombosis is a complex and multi-factorial adverse event. Patients may 
present with a variety of symptoms including power elevations, isolated rises in 
serum lactate dehydrogenase, clinically significant hemolysis, failure to 
adequately unload the left ventricle or worsening HF. The factors that may 
contribute to this adverse event could be pump-related, patient-related, or 
management related. In addition, patient profiles and management protocols vary 
from center to center, resulting in significant variability in reported pump 
thrombosis rates.  To reduce such variability a set of standard practices for 
surgical implantation and patient management were developed. These 
standardized practices are based on the HMII instruction for use with 
modifications derived from clinical practice. The impact of these standard 
practices on the incidence of HMII pump thrombosis will be assessed by 
PREVENT, a prospective, non-randomized multi-center study. The primary 
endpoint of PREVENT is the incidence of confirmed pump thrombosis within 
three months of HMII implantation. The secondary endpoints consist of the 
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incidence of confirmed pump thrombosis within six months of HMII implantation, 
incidence of suspected pump thrombosis (including unexplained hemolysis) 
within three and six months of HMII implantation, incidence of pump exchange, 
urgent transplantation or death due to pump thrombosis within three and six 
months of HMII implantation,  and analysis of risk factors for pump thrombosis. 
Additional information on PREVENT can be found on ClinicalTrials.gov (identifier: 
NCT02158403). The PREVENT study is currently enrolling and will enroll up to 
300 subjects from up to 20 sites.  
Studies Focused on Advancing Clinical Science 
RESTAGE-HF (REmission from Stage D Heart Failure)  
RESTAGE-HF is a multi-center study sponsored by the University of Louisville 
and funded by Thoratec.  The study was designed to determine the proportion of 
subjects treated with a standardized LVAD plus pharmacologic recovery and 
testing protocols who experience sufficient cardiac reverse remodeling to enable 
LVAD removal and remain free of mechanical circulatory support or heart 
transplantation for one-year post-LVAD removal.  The secondary endpoints 
consist of the time course of reverse remodeling on a left ventricular assist 
device, the time course and sustainability of reverse remodeling following LVAD 
explantation, the predictors of recovery and device removal, changes in 
functional capacity and quality of life. Additional information on RESTAGE-HF 
can be found on ClinicalTrials.gov (identifier: NCT01774656). The study is 
currently enrolling at 6 US sites.  
Conclusion 
Over the last decade significant improvements in survival and quality of life 
associated with the HeartMate II have been consistently achieved and 
demonstrated through the HMII BTT, DT, and post-approval trial data.6,7,8 To 
further expand the patient population who benefit from a HeartMate II device and 
to establish best practices for implant techniques and patient managements 
tailored to reduce adverse events, Thoratec sponsored and funded several post-
marketing studies.   Results from these studies will soon be published in peer 
reviewed journals and positively impact clinical practices.  
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